Cancer Immunotherapy
Your Body Already Knows How to Fight Cancer — It Just Needs Permission
For most of medical history, the idea of curing cancer by tweaking the immune system was considered fringe science — until a quiet researcher spent thirty years proving everyone wrong.
The Idea
Cancer is not an invasion from outside the body. It is the body's own cells, mutated and multiplying in ways they shouldn't — which creates a peculiar problem for the immune system, whose job is to distinguish 'self' from 'foreign threat.' Cancer exploits this. Tumour cells often carry surface proteins that act like a white flag, signalling to immune cells: nothing to see here, move along. These proteins — most famously PD-L1 — bind to receptors on T-cells (the immune system's frontline killers) and essentially apply the brakes. The T-cells detect the tumour, gear up for attack, then stand down. The cancer doesn't hide from the immune system; it bribes it. This is where immunotherapy intervenes — not by poisoning the cancer directly, as chemotherapy does, but by releasing those brakes. A class of drugs called checkpoint inhibitors blocks the PD-L1 handshake, stopping tumours from neutralising T-cells. Once freed, the immune system can do what it was already trying to do. The results can be dramatic: tumours that had spread throughout a body shrinking and sometimes disappearing entirely, in cases where conventional treatment had already failed. What makes this conceptually striking is the inversion it represents. Rather than introducing something foreign to fight the disease, immunotherapy restores the body's own capacity. The weapon was already there. The therapy just gets out of the way.
In the World
In the late 1980s, an immunologist named James Allison was studying a protein called CTLA-4, which functions as an off-switch on T-cells. His colleagues were mostly interested in it as a potential treatment for autoimmune disease — conditions where the immune system is too active. Allison had a different thought: what if you blocked CTLA-4 in cancer patients, to make the immune system more aggressive, not less? The idea was met with scepticism bordering on dismissal. Pharmaceutical companies passed. Immunology and oncology barely talked to each other as fields. Allison spent years refining the approach anyway, demonstrating in mice that blocking CTLA-4 caused tumours to regress. Eventually, the drug ipilimumab was developed based on his work. In 2010, clinical trials showed it extended survival in advanced melanoma — a cancer that, at that stage, had been almost universally fatal within a year. In 2018, Allison shared the Nobel Prize in Physiology or Medicine with Tasuku Honjo, who had independently discovered the PD-1 pathway — a second brake on the immune system, and the basis for a whole additional family of checkpoint inhibitors now used across dozens of cancer types. Allison, by most accounts, was driven not by career strategy but by genuine curiosity about a biological puzzle. He kept a harmonica in his lab coat pocket. He played in a band. He is not the archetype of a man who changed cancer treatment — which is perhaps exactly why he did.
Why It Matters
Most of us carry a vague, inherited fear of cancer as something that happens to you — a loss of control, a sentence handed down by biology or bad luck. Immunotherapy doesn't dissolve that fear, but it does quietly reframe it. The immune system, it turns out, is already surveilling for rogue cells constantly. Most cancers it catches before they establish. The ones that slip through have learned to speak the immune system's language and exploit its rules. Understanding this changes how you might think about your own body — not as passive territory where disease either strikes or doesn't, but as an active, ongoing negotiation between systems. It also raises questions worth holding: how you sleep, manage chronic stress, and whether you're under-or over-activating inflammatory responses all bear on immune function in ways researchers are still mapping. More broadly, the story of immunotherapy is a reminder that the most transformative ideas in any field often look wrong for a long time — not because the evidence was weak, but because they required people to think in a genuinely different register. Allison's insight wasn't more data. It was a different question.
A Question to Ponder
If your body is already running a constant, largely successful defence against abnormal cells, what does that change about how you relate to your own health — and what you might do, or stop doing, to support that process?
Get a new one of these every morning.
Start learning with Thinkable